Hamish Tadgell joined SGH in July 2015. He is Portfolio Manager of the SGH High Conviction Fund. Prior to this he worked at Goldman Sachs, where he was Chief Investment Officer - Australia for Global Investment Research. Hamish's distinguished career in investment markets and equity research spans 24 years, during which he has held positions in both Australia and the UK at JB Were and Goldman Sachs. Previously, Hamish spent seven years in professional services at Arthur Andersen. He holds a Bachelor of Economics from Monash University.
Is ResMed a buy as weight loss drugs reshape sleep apnoea?
ResMed's share price has slumped on fears weight loss drugs will shrink the sleep apnoea market. Here's what investors should know about the risks and long-term outlook.
Should you buy, hold or sell Chorus shares?
Chorus (ASX: CNU) is a unique opportunity to own an infrastructure utility business leveraged to the tailwinds of surging data demand and growing dividend.
Should you buy, hold or sell NextDC shares?
NXT is classified as a tech stock on the ASX, so why do we view it more as a social infrastructure and real estate investment?
Is Worley an emerging global sustainability player?
Worley made an early strategic shift to invest $100 million in building out its sustainability capacity, so is it paying off?
